Moi Laura, Stehlin Florian, Desseauve David, Ribi Camillo, Muller Yannick D
Service d'immunologie et allergie, Département de médecine, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Service d'obstétrique, Département femme-mère-enfant, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Rev Med Suisse. 2022 Apr 6;18(776):639-645. doi: 10.53738/REVMED.2022.18.776.639.
Intravenous iron infusions rarely result in severe hypersensitivity reactions. The primary suspected hypersensitivity mechanism is an abnormal complement activation by non-IgE antibodies to the carbohydrate moieties stabilizing iron formulations. A major risk factor for hypersensitivity reactions is related to the infusion speed. Fishbane-like reactions usually resolve after pausing the infusion, which can be resumed under medical surveillance and at a lower infusion rate. Yet, anaphylactic reactions require emergency first aid and subsequent strict avoidance of intravenous iron. Desensitization protocols can be implemented in selected cases and under strict medical surveillance to reduce the risks of severe reactions upon re-exposure.
静脉注射铁剂很少会导致严重的过敏反应。主要怀疑的过敏机制是针对稳定铁制剂碳水化合物部分的非IgE抗体异常激活补体。过敏反应的一个主要危险因素与输注速度有关。类菲什巴内反应通常在暂停输注后缓解,可在医学监测下以较低的输注速度恢复。然而,过敏反应需要紧急急救,随后严格避免静脉注射铁剂。在特定病例中并在严格的医学监测下可实施脱敏方案,以降低再次接触时发生严重反应的风险。